OmniAb (NASDAQ:OABIW – Get Free Report) will likely be announcing its results after the market closes on Friday, October 30th. Analysts expect the company to announce earnings of ($0.1271) per share and revenue of $3.49 million for the quarter.
OmniAb Stock Performance
OABIW traded up $0.03 during trading on Wednesday, hitting $0.41. The stock had a trading volume of 1,946 shares, compared to its average volume of 15,823. The company’s 50-day moving average price is $0.28 and its 200 day moving average price is $0.14. OmniAb has a twelve month low of $0.04 and a twelve month high of $0.42.
About OmniAb
OmniAb, Inc is a biotechnology company that develops antibody discovery technologies for the biopharmaceutical industry. Its platform is designed to help pharmaceutical and biotechnology companies identify therapeutic antibodies, including fully human and humanized antibodies, for potential use in treating diseases.
The company’s technology is based primarily on genetically engineered animal platforms that support the discovery of antibodies with targeted characteristics. Its offerings have included OmniRat, OmniMouse, OmniChicken, OmniFlic and OmniClic systems, which are intended to generate diverse antibody candidates against challenging biological targets.
Further Reading
- Five stocks we like better than OmniAb
- Palantir’s Q3 Bar Is Higher Than It Looks: 3 Numbers to Watch
- Johnson Controls Beats the Heat in AI Data Centers
- 3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead
- Is United Parcel Service Finally Turning the Corner?
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
